Oppenheimer set a $14.00 target price on ADMA Biologics (NASDAQ:ADMA) in a research note published on Tuesday, TipRanks reports. The brokerage currently has a buy rating on the biotechnology company’s stock.
ADMA has been the topic of several other research reports. Jefferies Financial Group initiated coverage on shares of ADMA Biologics in a research note on Tuesday, June 4th. They set a buy rating and a $8.00 price objective on the stock. HC Wainwright set a $13.00 price target on shares of ADMA Biologics and gave the stock a buy rating in a research report on Thursday, May 23rd. WBB Securities raised shares of ADMA Biologics to a buy rating in a research report on Thursday, April 4th. ValuEngine raised shares of ADMA Biologics from a hold rating to a buy rating in a research report on Wednesday, April 3rd. Finally, Maxim Group set a $12.00 price target on shares of ADMA Biologics and gave the stock a buy rating in a research report on Tuesday, April 2nd. Nine equities research analysts have rated the stock with a buy rating, The company currently has a consensus rating of Buy and an average target price of $11.17.
ADMA stock traded down $0.04 during trading on Tuesday, reaching $3.59. 517,223 shares of the company were exchanged, compared to its average volume of 1,072,352. The stock has a market cap of $209.09 million, a P/E ratio of -2.48 and a beta of 2.93. ADMA Biologics has a 52-week low of $2.08 and a 52-week high of $6.96. The firm’s 50 day moving average is $4.16. The company has a current ratio of 4.60, a quick ratio of 2.39 and a debt-to-equity ratio of 5.70.
ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.01. ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%. The company had revenue of $3.53 million for the quarter, compared to the consensus estimate of $2.96 million. Equities analysts expect that ADMA Biologics will post -1.04 earnings per share for the current fiscal year.
In other ADMA Biologics news, Director Lawrence P. Guiheen acquired 25,000 shares of the stock in a transaction dated Friday, May 17th. The shares were bought at an average price of $4.00 per share, with a total value of $100,000.00. Following the purchase, the director now directly owns 50,000 shares of the company’s stock, valued at approximately $200,000. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder Biotest Divestiture Trust sold 5,813,954 shares of ADMA Biologics stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $3.75, for a total transaction of $21,802,327.50. Following the completion of the transaction, the insider now directly owns 4,295,580 shares in the company, valued at approximately $16,108,425. The disclosure for this sale can be found here. In the last three months, insiders have acquired 4,064,500 shares of company stock worth $16,258,000. 18.80% of the stock is owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Diag Capital Management LP bought a new position in ADMA Biologics during the fourth quarter worth $435,000. JPMorgan Chase & Co. increased its position in ADMA Biologics by 54.7% during the third quarter. JPMorgan Chase & Co. now owns 228,999 shares of the biotechnology company’s stock worth $1,422,000 after acquiring an additional 81,003 shares during the period. Delek Group Ltd. increased its position in ADMA Biologics by 102.5% during the fourth quarter. Delek Group Ltd. now owns 118,539 shares of the biotechnology company’s stock worth $291,000 after acquiring an additional 60,000 shares during the period. Vanguard Group Inc. increased its position in ADMA Biologics by 5.2% during the third quarter. Vanguard Group Inc. now owns 1,192,641 shares of the biotechnology company’s stock worth $7,406,000 after acquiring an additional 58,610 shares during the period. Finally, Geode Capital Management LLC increased its position in ADMA Biologics by 14.4% during the fourth quarter. Geode Capital Management LLC now owns 276,930 shares of the biotechnology company’s stock worth $661,000 after acquiring an additional 34,818 shares during the period. 38.70% of the stock is currently owned by institutional investors.
About ADMA Biologics
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Read More: Forex
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.